SCHEMBL12065367

SCHEMBL12065367

CCC(Nc1cncc(-c2ccc(O)c(OC)c2)n1)c1cccc(NC(=O)c2cccnc2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 9/20 0.81
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ TSHR P16473 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HTT P42858 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ RET P07949 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ KIT P10721 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ FLT1 P17948 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12056834 0.94 CSF1R (0.79) CSF1RSMN1; SMN2TSHRALDH1A1KDM4E
SCHEMBL12056891 0.94 CSF1R (0.79) CSF1RSMN1; SMN2TSHRALDH1A1KDM4E
SCHEMBL13340183 0.91 CSF1R (0.68) CSF1RRETPDGFRBKITSRC
SCHEMBL13340175 0.91 CSF1R (0.67) CSF1RMEN1KMT2AMAPTRET
SCHEMBL13340176 0.91 CSF1R (0.67) CSF1RRETPDGFRBKITSRC
SCHEMBL13339821 0.90 CSF1R (1.00) CSF1RSMN1; SMN2TSHRALDH1A1HTT
SCHEMBL12104598 0.90 CSF1R (1.00) CSF1RSMN1; SMN2TSHRALDH1A1HTT
SCHEMBL12065013 0.88 CSF1R (0.62) CSF1RBRAF
SCHEMBL12064719 0.85 CSF1R (0.59) CSF1RBRAF
SCHEMBL12065330 0.85 CSF1R (0.59) CSF1RSMN1; SMN2TSHRALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084456-B2 Pyrazine-based tubulin inhibitors YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2011-12-27 — — US disclosed
US-20070082894-A1 Pyrazine-based tubulin inhibitors CYTOPIA PTY LTD (AU) 2007-04-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082894-A1 Pyrazine-based tubulin inhibitors TUBB1, TUBA1C, TUBB CSF1R 2097/4885SMN1; SMN2 2755/4885TSHR 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback